Over 50 years. One laboratory. Hundreds of studies on short peptides that most Western researchers still can't quite explain. Vadim Khavinson's work occupies a strange space in longevity science: too published to dismiss, too narrowly sourced to fully trust, and increasingly validated by researchers outside St. Petersburg. Understanding what he actually found — and what remains unresolved — is the starting point for any serious engagement with peptide bioregulators.
This is not a promotional overview. The research on Epitalon, Selank, and Semax includes genuinely interesting data. It also includes significant methodological limitations that anyone studying these compounds should understand clearly. Both things are true at once.
Who is Vadim Khavinson?
Vadim Khazratovich Khavinson is a Russian biogerontologist who has directed the Saint Petersburg Institute of Bioregulation and Gerontology since its founding. He holds professorships in gerontology and has published over 700 scientific papers, holds more than 200 patents, and is a member of the Russian Academy of Sciences and the European Academy of Sciences and Arts.
His core research program, launched in the 1970s, began with a straightforward observation: young organs function better than old ones, and if you extract and fractionate the signaling molecules from young tissue, you might transfer some of that function. The initial experiments used thymus and pineal gland extracts — cytomaxes — in aging animals and elderly humans. The results, by Russian clinical standards of the era, were positive enough to warrant pharmaceutical development.
Over the following decades, Khavinson's group moved from undefined organ extracts to defined synthetic peptides: the cytogens. The logic was elegant — if the active component of the thymus extract was a short peptide, synthesize just that peptide. Define its sequence. Test it in isolation. Epitalon (Ala-Glu-Asp-Gly), modeled on the pineal extract Epithalamin, became the flagship of this approach.
What makes Khavinson's body of work significant — even if you remain skeptical — is its volume and consistency. The same mechanisms appear across dozens of studies, different tissue types, and a 15-year human observational follow-up (PMID: 22451889). What makes it controversial is that most of this work has been validated primarily by Khavinson's own group, published in Russian journals, and has faced limited independent replication in Western research settings until very recently.
What Are Peptide Bioregulators?
The term “peptide bioregulator” is specific to Khavinson's framework. It does not simply mean “a biologically active peptide” — that category would include insulin, GLP-1, oxytocin, and thousands of other compounds. In Khavinson's definition, a peptide bioregulator is a short (typically 2–7 amino acid) peptide that acts not primarily through receptor agonism, but by entering cells and modulating gene expression at the chromatin level.
This is a mechanistically distinct claim. Classical therapeutic peptides work like keys: they bind specific receptor locks on cell surfaces and trigger downstream signaling cascades. Khavinson's peptide bioregulators are proposed to work more like transcription co-factors — small enough to penetrate nuclear compartments, bind to promoter regions of DNA, and influence which genes get expressed.
Two lines of evidence support this mechanism:
1. Gene expression modulation: A 2021 systematic review (Khavinson et al., Molecules, PMID: 34834147) catalogued the gene expression effects of multiple short peptides across dozens of studies, finding consistent patterns of epigenetic regulation — particularly involving genes related to cellular aging, DNA repair, and stress response.
2. Transport mechanisms: For this mechanism to work, the peptides need to actually get inside cells. A 2022 study (Khavinson et al., Int J Mol Sci, PMID: 35887081) demonstrated that ultrashort peptides can be transported intracellularly via POT (proton-coupled oligopeptide transporter) and LAT (large neutral amino acid transporter) carriers — the same transporters used for amino acid uptake. This resolves one of the early objections to the mechanism: peptides this small have real cellular uptake pathways.
The KE dipeptide (Lys-Glu), one of the simplest bioregulators, provides a useful model. In human mesenchymal stem cells, KE regulates SIRT1, PARP1, and PARP2 gene expression and protein synthesis during aging (Khavinson et al., Adv Gerontol 2023, PMID: 37782636). SIRT1 and PARP1/2 are central nodes in cellular aging and DNA repair — precisely the pathways a longevity-focused intervention would target.
Available from UNIK LAB
Epitalon 10mg
Research-grade Epitalon (Ala-Glu-Asp-Gly tetrapeptide) · HPLC verified ≥98% · COA included · 48h EU/UK dispatch
Cytogens vs Cytomaxes: The Two Families
Khavinson's peptide bioregulators fall into two distinct families that differ fundamentally in their composition and how they are produced.
| Property | Cytogens (Synthetic) | Cytomaxes (Extracts) |
|---|---|---|
| Origin | Chemically synthesized, defined sequence | Extracted from animal organ tissue |
| Composition | Single peptide (2–4 AA), reproducible | Complex mixture of short peptides, undefined |
| Key examples | Epitalon (AEDG), KE (Lys-Glu), EW (Glu-Trp) | Epithalamin (pineal), Thymalin (thymus), Cortexin (cortex) |
| Source organ | N/A (synthetic analog) | Pineal gland, thymus, liver, brain cortex, retina |
| Mechanistic clarity | High — single molecule, definable MOA | Low — complex mixture, attribution unclear |
| Russian regulatory status | Some approved as drugs (e.g., Thymulin analogs) | Approved as drugs in Russia (Epithalamin, Thymalin, Cortexin) |
The evolution from cytomaxes to cytogens mirrors a broader trend in pharmacology: extract an active ingredient from a natural source, identify its structure, synthesize it cleanly. The advantage for research is obvious — you can study a defined compound, control dosing precisely, and establish reproducible results. Epitalon is the clearest example of this progression.
Epitalon: The Flagship Bioregulator
Epitalon — sequence Ala-Glu-Asp-Gly, four amino acids — is the synthetic equivalent of the active fraction of Epithalamin, a polypeptide extract from the bovine pineal gland. The pineal connection matters: the pineal gland governs circadian rhythms through melatonin and has long been implicated in biological aging. Age-related pineal calcification and reduced melatonin production are among the most consistent markers of aging across species.
Telomerase activation: what the data shows
The most cited Epitalon finding is its effect on telomere biology. In 2003, Khavinson, Bondarev, and Butyugov published a study in Bulletin of Experimental Biology and Medicine (PMID: 12937682) demonstrating that Epitalon activated hTERT — the catalytic subunit of telomerase — in human somatic cells in vitro. Cells treated with Epitalon showed measurable telomere elongation and continued to divide beyond their normal Hayflick limit.
A 2004 follow-up (PMID: 15455129) confirmed the division limit extension. Cells that would normally stop dividing after a finite number of doublings continued proliferating when treated with Epitalon. The proposed mechanism: Epitalon enters the nucleus, binds to chromatin regulatory regions near the hTERT promoter, and upregulates its expression.
These results would be extraordinary if fully validated. Telomere shortening is one of the most established hallmarks of cellular aging. A compound that reverses it in human cells — even in vitro — commands attention.
Pineal function and hormonal effects
Beyond telomere biology, Epitalon's pineal origin has driven research into neuroendocrine aging. Goncharova and Khavinson (Exp Gerontol 2005, PMID: 15664732) showed that pineal peptides could restore age-related disturbances in the hormonal functions of both the pineal gland and pancreas in aged primates. The pattern — disrupted circadian hormone output, partially restored by pineal-derived peptide — has been replicated in multiple animal models.
The 15-year human follow-up
The longest-duration human study in the Khavinson literature is an observational follow-up published in Bull Exp Biol Med (Korkushko, Khavinson et al., 2011, PMID: 22451889). It reported that elderly participants receiving a pituitary peptide geroprotector showed slower progression of aging biomarkers over 15 years compared to controls. This is not a randomized controlled trial — it's observational with all the confounding that entails — but it is the closest thing to long-term human evidence in this literature.
The honest limitations
The Epitalon data is almost entirely from Khavinson's group, with the partial exception of a 2025 study from Brunel University (Al-Dulaimi et al.) that provided the first non-Russian in vitro replication of dose-dependent telomere elongation. That's important: the fundamental finding has now been independently confirmed at the cellular level. What has not been confirmed in independent settings: any clinical benefit in humans. There are no randomized controlled trials in Western literature showing that Epitalon extends human lifespan or produces measurable health outcomes.
The research is interesting. The limitations are real. Both deserve equal weight.
→ For deep-dive coverage of the telomere data, see: Epitalon and Telomeres: The Longevity Peptide Explained
Selank: Anxiolytic Neuropeptide Research
Selank (sequence TPLRPG, a heptapeptide) is a stabilized analog of the endogenous tetrapeptide tuftsin (TKPR). It was developed not at Khavinson's institute but at the Institute of Molecular Genetics of the Russian Academy of Sciences — though it belongs to the same class of Russian-developed regulatory peptides and is often grouped with Khavinson's work in the peptide bioregulator literature.
The “stabilized analog” designation is important. Natural tuftsin is rapidly degraded by serum peptidases. Adding the Pro-Gly-Pro sequence to the C-terminus dramatically extends its half-life without altering its core activity. This is standard peptidomimetic chemistry applied to a naturally occurring regulatory peptide.
Anxiolytic effects: the rodent data
Kasian et al. (Behavioural Neurology, 2017, PMID: 28280289) showed that Selank enhanced the anxiolytic effects of diazepam under unpredictable chronic mild stress conditions in rats. The proposed mechanism involves GABAergic modulation — Selank appears to potentiate GABA-A receptor signaling without the tolerance-inducing effects of classical benzodiazepines. This is a significant pharmacological distinction: a peptide that achieves anxiolysis through GABAergic pathways but without direct benzodiazepine receptor binding could theoretically avoid tolerance development.
BDNF upregulation and memory protection
Kolik et al. (Bull Exp Biol Med, 2019, PMID: 31625062) found that Selank protected against ethanol-induced memory impairment in rats by regulating BDNF content in the hippocampus. Brain-derived neurotrophic factor (BDNF) is among the most important modulators of synaptic plasticity and memory consolidation. Alcohol reduces hippocampal BDNF; Selank restored it. This finding connects the Selank and Semax research programs — BDNF upregulation appears to be a shared mechanism.
Russian regulatory status and limitations
Selank is approved in Russia as a treatment for generalized anxiety disorder. It has been in clinical use there since the early 2000s. Outside Russia, it remains a research compound. The clinical evidence base consists primarily of Russian studies with limited patient numbers and no double-blind placebo-controlled trials published in high-impact Western journals.
→ Detailed Selank research coverage: Selank Peptide Research Guide
Available from UNIK LAB
Selank 5mg
Research-grade Selank (TPLRPG heptapeptide) · HPLC verified ≥98% · COA included · 48h EU/UK dispatch
Semax: BDNF Upregulation and Neuroprotection
Semax (MHFPGP) is a synthetic heptapeptide analog of the ACTH(4–7) fragment: Met-Glu-His-Phe-Pro-Gly-Pro. Like Selank, it was developed at the Institute of Molecular Genetics under the group of Nikolai Myasoedov. It addresses a different target than Epitalon (telomeres) or Selank (anxiety): neuroprotection and cognitive function under stress, particularly ischemic stress.
Neurotrophin activation after ischemia
The most mechanistically significant Semax paper for neuroprotection is Dmitrieva et al. (Cell Mol Neurobiol, 2010, PMID: 19633950): Semax and its metabolite Pro-Gly-Pro activated the transcription of BDNF and NGF (nerve growth factor) and their receptor genes in rat brain after cerebral ischemia. Both neurotrophins are essential for neuron survival after ischemic insult. Semax increased their transcription during the critical post-ischemic window.
What makes this particularly relevant: stroke is characterized by an acute neurotrophin deficit in the ischemic zone, and the speed of neurotrophin recovery is a key determinant of neurological outcome. A peptide that accelerates BDNF and NGF transcription in this window addresses a real unmet need — which is why Semax was approved for ischemic stroke in Russia.
Cognitive enhancement in preclinical models
Beyond ischemia, Semax has shown cognitive-enhancing properties in a range of preclinical models — stress-induced memory impairment, sleep deprivation, and normal aging models. The proposed mechanism in non-ischemic contexts is similar: BDNF upregulation in hippocampus and prefrontal cortex, supporting synaptic plasticity and working memory. These findings are consistent across multiple Russian research groups, which adds some confidence — they are not all originating from a single laboratory.
Russian clinical data and limitations
Semax has been used in Russian clinical practice for ischemic stroke and some cognitive applications for over two decades. The clinical literature is largely in Russian, published in Russian journals, with small trial sizes by Western regulatory standards. No Western Phase 2 or Phase 3 trial data exists. From a European research standpoint, Semax is an intriguing neuroprotective compound with solid preclinical rationale and meaningful Russian clinical use — but absent from the Western evidence base.
→ Detailed Semax research coverage: Semax Peptide: BDNF and Neuroprotection Research Guide
Available from UNIK LAB
Semax 5mg
Research-grade Semax (MHFPGP heptapeptide) · HPLC verified ≥98% · COA included · 48h EU/UK dispatch
The Research Landscape: What We Know, What We Don't
Khavinson's bioregulator program generates a predictable response in Western research circles: initial skepticism (too many positive results from a single group, published in low-impact journals), followed by cautious interest as the mechanistic data becomes more solid, followed by a slow process of independent validation. That process is underway — the 2025 Brunel Epitalon study is a data point in it — but it remains early.
Here is an honest summary of the research landscape as of mid-2026:
What the data supports
- Telomerase activation in vitro (Epitalon): Demonstrated by Khavinson group (PMID: 12937682) and independently replicated in cell culture at Brunel University (2025). The mechanism — hTERT promoter upregulation — is biologically plausible.
- GABAergic anxiolytic effects (Selank): Consistent across multiple rodent studies from different Russian groups. BDNF upregulation adds a neuroplasticity dimension.
- Neurotrophin upregulation post-ischemia (Semax): Mechanistically well-described in animal models; supported by Russian clinical use for stroke.
- Gene expression modulation: The 2021 systematic review (PMID: 34834147) synthesizes strong evidence that short Khavinson peptides systematically influence gene expression, including aging-related pathways.
What remains unvalidated
- Human longevity outcomes: No randomized controlled trial has measured Epitalon's effect on human lifespan, all-cause mortality, or validated biomarkers of aging. The 15-year observational study (PMID: 22451889) is hypothesis-generating, not confirmatory.
- Clinical anxiolytic efficacy (Selank) in Western populations: Russian approval exists; independent double-blind trials meeting Western clinical standards do not.
- Semax in non-ischemic cognitive applications: Solid preclinical data; weak clinical evidence outside Russian literature.
- Long-term safety profile: All three compounds have been in use for decades in Russia without major reported adverse events — but absence of reported events in a system with limited pharmacovigilance infrastructure is not the same as proven safety.

Compound Comparison Table
The three compounds most relevant to the Khavinson bioregulator cluster differ substantially in their targets, research depth, and regulatory status. This table synthesizes the key dimensions:
| Compound | Sequence | Primary Research Target | Key Human Evidence | EU/US Status |
|---|---|---|---|---|
| Epitalon | AEDG (4 AA) | Telomere biology, pineal aging, epigenetic regulation | 15-year observational study; no RCT for longevity | Research compound only |
| Selank | TPLRPG (7 AA) | Anxiolytic, GABAergic modulation, BDNF/memory | Russian approval for anxiety; limited independent RCTs | Research compound only |
| Semax | MHFPGP (7 AA) | Neuroprotection, BDNF/NGF upregulation, ischemia | Russian approval for stroke; Russian clinical studies | Research compound only |
| KE dipeptide | KE (2 AA) | SIRT1/PARP regulation, stem cell aging | Preclinical only; no human trials | Research compound only |
| Epithalamin | Complex extract | Pineal/circadian, melatonin restoration | Russian clinical use; older observational data | Not standardly available outside Russia |
Frequently Asked Questions
Who is Vadim Khavinson and why does his research matter?
Vadim Khavinson has directed the Saint Petersburg Institute of Bioregulation and Gerontology for over four decades and has published more than 700 scientific papers on short regulatory peptides. His work matters because it represents the most systematic, long-duration research program focused on organ-derived short peptides and biological aging. Even if Western replication remains limited, the volume and internal consistency of the data make it a significant body of literature — particularly as independent validation has begun to emerge.
What is the difference between cytogens and cytomaxes?
Cytogens are synthetic peptides with a defined sequence (e.g., Epitalon = Ala-Glu-Asp-Gly). Cytomaxes are natural organ extracts containing a complex, undefined mixture of short peptides (e.g., Epithalamin from pineal gland, Thymalin from thymus). Cytogens are more amenable to rigorous scientific study because their composition is controlled and reproducible. Cytomaxes were the first clinical applications but are harder to study mechanistically.
What does the Epitalon telomerase research actually show?
Cell culture studies from the Khavinson group (PMID: 12937682, 2003) showed that Epitalon activated hTERT (telomerase catalytic subunit) in human somatic cells and enabled telomere elongation and extension beyond the Hayflick limit. A 2025 independent study from Brunel University replicated dose-dependent telomere elongation in vitro. These are in vitro findings. Large-scale human clinical trials confirming longevity outcomes do not exist yet.
What is the research status of Selank?
Preclinical data shows anxiolytic effects via GABAergic modulation (PMID: 28280289) and BDNF upregulation with memory protection (PMID: 31625062). Selank is approved in Russia for anxiety disorders. Outside Russia, it remains a research compound without independent double-blind trials meeting Western regulatory standards.
What does the Semax research show about BDNF?
Dmitrieva et al. (2010, PMID: 19633950) demonstrated that Semax activates BDNF and NGF transcription in rat brain following cerebral ischemia. Semax is approved in Russia for ischemic stroke treatment. The BDNF-upregulating mechanism is well-documented in preclinical models; independent Western clinical data is limited.
What are the main limitations of Khavinson bioregulator research?
Key limitations: (1) most studies from the same Russian research group; (2) published in lower-impact Russian journals; (3) majority is preclinical; (4) limited Western replication until very recently; (5) no RCTs for longevity outcomes. These do not invalidate the data but require cautious interpretation. The mechanistic framework is coherent and increasingly supported by independent groups.
How do peptide bioregulators differ from classical therapeutic peptides?
Classical peptides typically act as receptor agonists/antagonists at cell surfaces. Khavinson's bioregulators are proposed to enter cells and modulate gene expression at the chromatin level — acting more like regulatory transcription co-factors than receptor ligands. Transport via intracellular POT/LAT carriers (PMID: 35887081) and gene expression regulation (PMID: 34834147) support this mechanistic distinction.
Cluster Articles
